|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 39/00 | (2006.01) |
| A61K 39/395 | (2006.01) | ||
| A61P 35/02 | (2006.01) | ||
| C07K 16/28 | (2006.01) | ||
| C07K 16/30 | (2006.01) | ||
| A61P 37/06 | (2006.01) | ||
| C07K 14/435 | (2006.01) | ||
| C07K 16/18 | (2006.01) |
| (11) | Number of the document | 3893924 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19832737.1 |
| Date of filing the European patent application | 2019-12-13 | |
| (97) | Date of publication of the European application | 2021-10-20 |
| (45) | Date of publication and mention of the grant of the patent | 2024-08-21 |
| (46) | Date of publication of the claims translation | 2024-10-10 |
| (86) | Number | PCT/IB2019/060802 |
| Date | 2019-12-13 |
| (87) | Number | WO 2020/121282 |
| Date | 2020-06-18 |
| (30) | Number | Date | Country code |
| 201862779102 P | 2018-12-13 | US |
| (72) |
BLANCHETOT, Christophe , BE
DE HAARD, Hans , NL
|
| (73) |
argenx BV ,
Industriepark 7, 9052 Zwijnaarde,
BE
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Antikūnai žmogaus komplemento faktoriui C2b ir jų panaudojimo būdai |
| ANTIBODIES TO HUMAN COMPLEMENT FACTOR C2B AND METHODS OF USE |
| Payment date | Validity (years) | Amount | |
| 2025-11-18 | 7 | 162.00 EUR |
| 2026-12-13 |